此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Does the Fecal Microbiome Influence Rotarix Immunogenicity

2014年8月19日 更新者:Vanessa Harris、Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Nested Case-control Analysis of the Influence of the Microbiome on Rotavirus Vaccine Immunogenic Response in Infants in Karachi, Pakistan

This is a proposal for a nested case-control study within an ongoing rotavirus vaccine immunogenicity clinical trial Karachi, Pakistan. The primary study aim is to compare the fecal microbiota composition and diversity of infants who do (control) and do not (case) demonstrate immune seroconversion to rotavirus vaccination. The infants will be matched for vaccination dose, age and breast-feeding practices.

研究概览

研究类型

观察性的

注册 (实际的)

76

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

4周 及以上 (孩子、成人、年长者)

接受健康志愿者

有资格学习的性别

全部

取样方法

非概率样本

研究人群

The study will be nested within an existing rotavirus immunogenicity study being conducted in Karachi, Pakistan (clinicaltrials.gov: NCT01199874) . The physical setting is a peri-urban slum outside of Karachi, primarily populated by fishermen. Parents and legal guardians of infants participating in NCT01199874 will provide new informed consent for inclusion in this study.

描述

Inclusion Criteria:

  • 6 weeks 0 days to 7 weeks 6 days age at the time of enrollment.
  • Healthy infant free of chronic or serious medical condition as determined by history and physical exam at time of enrollment into in the study.
  • Written informed consent obtained from the parents or guardians.
  • Availability of baseline fecal sample collected before Rotarix vaccination
  • Written informed consent obtained from the parents or guardians for nested study

Exclusion Criteria:

  • Hypersensitivity to any of the vaccine components
  • Use of any investigational drug or vaccine other than the study vaccine within 30 days of first dose of study vaccine or during the study.
  • Use of any immunosuppressive drugs.
  • Previous intussusceptions or abdominal surgery.
  • Enrollment in any other trial (besides NCT01199874).
  • Birth weight less than 1500 grams; or if birth weight is unknown, weight less than 2000 grams on or before 28 days.
  • Immunoglobulin and/or blood products use since birth or during the study period. Nested study additional exclusion criteria:
  • Positive serum anti-rotavirus Immunoglobulin A (> 20 U/ml) at 6 weeks of age, indicative of prior rotavirus infection

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:病例对照
  • 时间观点:预期

队列和干预

团体/队列
Case: non-rotavirus seroconverters
Infants not demonstrating seroconversion to rotavirus vaccination, as measured anti-RV Immunoglobulin A < 20 U/ml
Control: rotavirus seroconverters
Infants demonstrating seroconversion to rotavirus vaccination, as measured by anti-rotavirus Immunoglobulin A > 20 U/ml

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
microbiome diversity (Shannon's index) and composition (relative abundance)
大体时间:at 6 weeks of age, pre-rotavirus vaccination

Microbiota composition will be measured by calculating and comparing a % of the phylogenetic groups present in both groups

Diversity will be measured by calculating a comparing a Shannon's reciprocal index of diversity, 1/D in both groups

The relative abundance of microbial groups will be measured by calculating and comparing the ribosomal ribonucleic acid gene copy per gram of feces over time in both groups

at 6 weeks of age, pre-rotavirus vaccination

次要结果测量

结果测量
措施说明
大体时间
microbiome diversity (Shannon's index) and composition (relative abundance)
大体时间:at 1 to 3 years of age post-rotavirus vaccination

Microbiota composition post vaccination will be measured by calculating and comparing a % of the phylogenetic groups present in both groups

Diversity post vaccination will be measured by calculating a comparing a Shannon's reciprocal index of diversity, 1/D in both groups

The relative abundance of microbial groups post vaccination will be measured by calculating and comparing the ribosomal ribonucleic acid gene copy per gram of feces over time in both groups

at 1 to 3 years of age post-rotavirus vaccination

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Vanessa C Harris, MD、Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2013年9月1日

初级完成 (实际的)

2013年11月1日

研究完成 (实际的)

2013年11月1日

研究注册日期

首次提交

2014年6月10日

首先提交符合 QC 标准的

2014年8月19日

首次发布 (估计)

2014年8月20日

研究记录更新

最后更新发布 (估计)

2014年8月20日

上次提交的符合 QC 标准的更新

2014年8月19日

最后验证

2014年8月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

在美国制造并从美国出口的产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅